Very young children can benefit from a high level of immunity to the novel coronavirus after receiving the Comirnaty vaccine, new research shows.
New York-based pharma giant Pfizer (NYSE: PFE), together with the vaccine’s originator, Germany’s BioNTech (Nasdaq: BNTX), today announced updated efficacy results from a Phase II/III trial enrolling children aged between six months and four years.
The US Food and Drug Administration has already granted an Emergency Use Authorization (EUA) for this age group, on June 17, while the European Medicines Agency continues to review the data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze